12488 Federal Register / Vol. 80, No. 45 / Monday, March 9, 2015 / Notices 

information collection that has been 

extended, revised, or implemented on or 

after October 1, 1995, unless it displays 

a currently valid OMB control number. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, OIRA_submission@

omb.eop.gov or by fax to 202–395–6974, 

Attention: NIH Desk Officer. 

Comment Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments or request more 

information on the proposed project 

contact: Anthony Dickherber, NCI 

Center for Strategic Scientific Initiatives, 

31 Center Drive, Rm10A33, Bethesda, 

MD 20892 or call non-toll-free number 

301–547–9980 or Email your request, 

including your address to: 

dickherberaj@mail.nih.gov. Formal 

requests for additional plans and 

instruments must be requested in 

writing. 

Proposed Collection: Surveys and 

Interviews to Support an Evaluation of 

the Innovative Molecular Analysis 

Technologies (IMAT) Program (NCI), 

0925–NEW, National Cancer Institute 

(NCI), National Institutes of Health 

(NIH). 

Need and Use of Information 

Collection: The purpose of the proposed 

evaluation is to pursue a comprehensive 

process and outcome assessment of the 

15-year old Innovative Molecular 

Analysis Technologies (IMAT) program. 

While the program consistently offers 

promising indicators of success, the full 

program has not been evaluated since 

2008, and never in as comprehensive a 

manner as has been formulated in the 

current evaluation plan. An outcome 

evaluation of the long-standing National 

Cancer Institute’s (NCI) IMAT program 

presents a rich and unique opportunity 

likely to serve institutes across the 

National Institutes of Health (NIH), and 

perhaps other federal agencies, 

considering the costs and benefits of 

directing resources towards supporting 

technology development. An award 

through the NIH Evaluation Set-Aside 

program to support this evaluation, for 

which NIH-wide relevance is a principle 

element of determining merit for 

support, is testament to this. The 

evaluation serves as an opportunity to 

gauge the impact of investments in 

technology development and also to 

assess the strengths and weaknesses of 

phased innovation award mechanisms. 

Like all institutes and centers (ICs) of 

the NIH, NCI seeks opportunities for 

improving their programs’ utility for the 

broad continuum of researchers, 

clinicians and ultimately patients. NCI 

Director Harold Varmus and other 

leadership across NCI, as well as the 

NCI Board of Scientific Advisors, will 

be the primary users of the evaluation 

results. Findings are primarily intended 

for considering the long-term strategy to 

support innovative technology 

development and how to more 

efficiently translate emerging 

capabilities through such technologies 

into the promised benefits for cancer 

research and clinical care. Interviews 

with grantees, program officers, review 

officers, and other NIH awardees make 

up a crucial component of the 

evaluation plan and will largely follow 

set survey protocols. Specific near-term 

aims include the use of this information 

to consider the utility of continued 

investment through existing 

solicitations and in strategic planning 

generally for institute support for 

innovative technology development. 

OMB approval is requested for 1 year. 

There are no costs to respondents other 

than their time. The total estimated 

annualized burden hours are 575. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of 

respondents 

Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total annual 

burden 

(in hours) 

IMAT Awardee Interview ............... IMAT Awardees ............................................... 100 1 1 100 

Evaluation Web-based Survey ...... IMAT Applicants and Other NIH Awardees ..... 900 1 30/60 450 

Tech End Users Interview ............. Technology End-Users .................................... 50 1 30/60 25 

Dated: February 23, 2015. 

Karla Bailey, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 2015–05298 Filed 3–6–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10555] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, HHS. 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information (including each proposed 

extension or reinstatement of an existing 

collection of information) and to allow 

60 days for public comment on the 

proposed action. Interested persons are 

invited to send comments regarding our 

burden estimates or any other aspect of 

this collection of information, including 

any of the following subjects: (1) The 

necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions; 

(2) the accuracy of the estimated 

burden; (3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) the use of 

automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

DATES: Comments must be received by 

May 8, 2015. 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number. To be assured 

consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 80, No. 45 / Monday, March 9, 2015 / Notices 12489 

Submission’’ or ‘‘More Search Options’’ 

to find the information collection 

document(s) that are accepting 

comments. 

2. By regular mail. You may mail 

written comments to the following 

address: CMS, Office of Strategic 

Operations and Regulatory Affairs, 

Division of Regulations Development, 

Attention: Document Identifier/OMB 

Control Number llll, Room C4–26– 

05, 7500 Security Boulevard, Baltimore, 

Maryland 21244–1850. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ Web site address at 

http://www.cms.hhs.gov/Paperwork

ReductionActof1995. 

2. Email your request, including your 

address, phone number, OMB number, 

and CMS document identifier, to 

Paperwork@cms.hhs.gov. 

3. Call the Reports Clearance Office at 

(410) 786–1326. 

FOR FURTHER INFORMATION CONTACT: 

Reports Clearance Office at (410) 786– 

1326. 

SUPPLEMENTARY INFORMATION: 

Contents 

This notice sets out a summary of the 

use and burden associated with the 

following information collections. More 

detailed information can be found in 

each collection’s supporting statement 

and associated materials (see 

ADDRESSES). 

CMS–10555 Small Business Health 

Options Program (SHOP) Effective Date 

and Termination Notice Requirements 

Under the PRA (44 U.S.C. 3501– 

3520), federal agencies must obtain 

approval from the Office of Management 

and Budget (OMB) for each collection of 

information they conduct or sponsor. 

The term ‘‘collection of information’’ is 

defined in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA 

requires federal agencies to publish a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, before 

submitting the collection to OMB for 

approval. To comply with this 

requirement, CMS is publishing this 

notice. 

Information Collection 

1. Type of Information Collection 

Request: New collection (Request for a 

new OMB control number); Title of 

Information Collection: Small Business 

Health Options Program (SHOP) 

Effective Date and Termination Notice 

Requirements; Use: We are requiring 

that for plan years beginning on or after 

January 1, 2017, the Small Business 

Health Options Program (SHOP) must 

ensure that a qualified health plan 

(QHP) issuer notifies qualified 

employees, enrollees, and new enrollees 

in a QHP through the SHOP of the 

effective date of coverage. As required 

by the Patient Protection and Affordable 

Care Act; HHS Notice of Benefit and 

Payment Parameter for 2016 (CMS– 

9944–F), which published February 27, 

2015, if any enrollee’s coverage through 

the SHOP is terminated due to nonpayment of premiums or a loss of the 

enrollee’s or employer group’s eligibility 

to participate in the SHOP, the SHOP 

must notify the enrollee or the qualified 

employer of the termination of such 

coverage. In the termination of coverage 

the SHOP must include the termination 

date and reason for termination to the 

enrollee or qualified employer. Form 

Number: CMS–10555 (OMB Control 

Number: 0938–New); Frequency: 

Annually; Affected Public: Private 

sector (Business or other for profits and 

Not-for-profit institutions); Number of 

Respondents: 445; Total Annual 

Responses: 1,335; Total Annual Hours: 

46,725. (For policy questions regarding 

this collection contact Christelle Jang at 

(410) 786–8438). 

Dated: March 4, 2015. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2015–05420 Filed 3–6–15; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Committee on Organ 

Transplantation (ACOT) 

AGENCY: Health Resources and Services 

Administration (HRSA), HHS. 

ACTION: Notice; correction. 

SUMMARY: The Health Resources and 

Services Administration published a 

notice in the Federal Register, FR 2015– 

03929 (February 26, 2015), announcing 

the meeting for the Advisory Committee 

on Organ Transplantation (ACOT). This 

action is to add dial-in information. 

Correction: In the Federal Register, 

FR 2015–03929 (February 26, 2015), 

please make the following addition: 

Participants can also join this meeting via 

conference call by calling the toll-free phone 

number 888–324–4391 and providing the 

participant pass code 7744447. 

Jackie Painter, 

Director, Division of the Executive Secretariat. 

[FR Doc. 2015–05415 Filed 3–6–15; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Collaborative 

Interdisciplinary Team Science in NIDDK 

Research Areas (R24)–Hematopoiesis. 

Date: March 20, 2015. 

Time: 2:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Paul A. Rushing, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 747, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8895, 

rushingp@extra.niddk.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; RFA–DK14–011 

Chronic Kidney Disease Biomarkers 

Consortium (CKD BioCon) (U01). 

Date: March 24, 2015. 

Time: 11:30 a.m. to 3:30 p.m. 

mstockstill on DSK4VPTVN1PROD with NOTICES